[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201505993PA - Azole benzene derivative - Google Patents

Azole benzene derivative

Info

Publication number
SG11201505993PA
SG11201505993PA SG11201505993PA SG11201505993PA SG11201505993PA SG 11201505993P A SG11201505993P A SG 11201505993PA SG 11201505993P A SG11201505993P A SG 11201505993PA SG 11201505993P A SG11201505993P A SG 11201505993PA SG 11201505993P A SG11201505993P A SG 11201505993PA
Authority
SG
Singapore
Prior art keywords
benzene derivative
azole benzene
azole
derivative
benzene
Prior art date
Application number
SG11201505993PA
Inventor
Asahi Kawana
Chikashi Kanazawa
Yoshimasa Takahashi
Takashi Shirakura
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of SG11201505993PA publication Critical patent/SG11201505993PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11201505993PA 2013-01-31 2014-01-30 Azole benzene derivative SG11201505993PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013017167 2013-01-31
PCT/JP2014/052154 WO2014119681A1 (en) 2013-01-31 2014-01-30 Azole benzene derivative

Publications (1)

Publication Number Publication Date
SG11201505993PA true SG11201505993PA (en) 2015-08-28

Family

ID=51262388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505993PA SG11201505993PA (en) 2013-01-31 2014-01-30 Azole benzene derivative

Country Status (36)

Country Link
US (1) US9388174B2 (en)
EP (1) EP2952513B1 (en)
JP (1) JP5734532B2 (en)
KR (1) KR102199258B1 (en)
CN (1) CN104968662B (en)
AR (1) AR095098A1 (en)
AU (1) AU2014213396B2 (en)
BR (1) BR112015018033B1 (en)
CA (1) CA2897928C (en)
CL (1) CL2015002117A1 (en)
CY (1) CY1122015T1 (en)
DK (1) DK2952513T3 (en)
ES (1) ES2744817T3 (en)
HK (1) HK1215806A1 (en)
HR (1) HRP20191554T1 (en)
HU (1) HUE047028T2 (en)
IL (2) IL239940B (en)
LT (1) LT2952513T (en)
MA (1) MA38295B1 (en)
ME (1) ME03516B (en)
MX (1) MX364483B (en)
MY (1) MY181731A (en)
NZ (1) NZ709407A (en)
PE (1) PE20151329A1 (en)
PH (2) PH12015501640B1 (en)
PL (1) PL2952513T3 (en)
PT (1) PT2952513T (en)
RS (1) RS59371B1 (en)
RU (1) RU2641891C2 (en)
SA (1) SA515360829B1 (en)
SG (1) SG11201505993PA (en)
SI (1) SI2952513T1 (en)
TW (1) TWI606048B (en)
UA (1) UA117124C2 (en)
WO (1) WO2014119681A1 (en)
ZA (1) ZA201505240B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015009602A (en) 2013-01-31 2015-11-25 Vertex Pharma Pyridone amides as modulators of sodium channels.
NZ760006A (en) 2013-12-13 2022-07-29 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
US20170217948A1 (en) * 2014-07-30 2017-08-03 Teijin Pharma Limited Xanthine oxidase inhibitor
MX370524B (en) * 2014-07-30 2019-12-17 Teijin Pharma Ltd Azole benzene derivative and crystal thereof.
EP3176165B1 (en) * 2014-07-30 2018-09-26 Teijin Pharma Limited Crystal of azole benzene derivative as xanthine oxidase inhibitor
ES2842577T3 (en) 2016-02-19 2021-07-14 Nezu Life Science Co Ltd Therapeutic or prophylactic drug for dementia
TW201828939A (en) * 2016-11-28 2018-08-16 日商帝人製藥股份有限公司 Therapeutic drug or prophylactic drug for diabetic nephropathy
UA124857C2 (en) 2017-05-16 2021-12-01 Вертекс Фармасьютикалз Інкорпорейтед Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
TW202002971A (en) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 A method of treating pain
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CA3221259A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (en) 1990-11-30 1996-12-01 Teijin Ltd DERIVATIVE OF 2-ARYLTIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME.
ATE270550T1 (en) 1995-04-07 2004-07-15 Teijin Ltd ACTIVE SUBSTANCE TO PROTECT ORGANS OR TISSUES
ATE210132T1 (en) * 1995-04-21 2001-12-15 Neurosearch As BENZMIDAZOLE COMPOUNDS AND THEIR USE AS MODULATORS OF THE GABAA RECEPTOR COMPLEX
JP2002105067A (en) 2000-09-28 2002-04-10 Teijin Ltd 2-phenylthiazone derivative and medicine composition comprising the same as active ingredient
US7947707B2 (en) 2005-10-07 2011-05-24 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2008126770A1 (en) * 2007-04-05 2008-10-23 Astellas Pharma Inc. Method for producing triarylcarboxylic acid derivative
EP2133331A4 (en) 2007-04-11 2011-06-22 Kissei Pharmaceutical 5-membered heterocyclic derivative and use thereof for medical purposes
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
EP2536699A2 (en) 2010-02-19 2012-12-26 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
US8969582B2 (en) 2010-04-29 2015-03-03 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat

Also Published As

Publication number Publication date
LT2952513T (en) 2019-10-25
MY181731A (en) 2021-01-05
IL239940A0 (en) 2015-08-31
PT2952513T (en) 2019-09-27
HRP20191554T1 (en) 2019-11-29
US9388174B2 (en) 2016-07-12
EP2952513A1 (en) 2015-12-09
JPWO2014119681A1 (en) 2017-01-26
CY1122015T1 (en) 2020-10-14
KR20150112955A (en) 2015-10-07
BR112015018033A8 (en) 2019-11-05
HUE047028T2 (en) 2020-04-28
ES2744817T3 (en) 2020-02-26
PH12018500261A1 (en) 2018-09-10
CA2897928C (en) 2021-02-16
MX2015009655A (en) 2015-12-07
PH12015501640A1 (en) 2015-10-12
CA2897928A1 (en) 2014-08-07
EP2952513B1 (en) 2019-07-10
AU2014213396A1 (en) 2015-07-23
CN104968662A (en) 2015-10-07
JP5734532B2 (en) 2015-06-17
MA38295B1 (en) 2018-04-30
HK1215806A1 (en) 2016-09-15
SA515360829B1 (en) 2018-10-11
AU2014213396B2 (en) 2017-05-11
ZA201505240B (en) 2016-08-31
BR112015018033A2 (en) 2017-07-11
CL2015002117A1 (en) 2015-10-30
PE20151329A1 (en) 2015-10-12
TW201443047A (en) 2014-11-16
IL259824B (en) 2020-04-30
MA38295A1 (en) 2017-12-29
WO2014119681A1 (en) 2014-08-07
UA117124C2 (en) 2018-06-25
RU2015132105A (en) 2017-02-03
RU2641891C2 (en) 2018-01-23
AR095098A1 (en) 2015-09-30
PH12015501640B1 (en) 2015-10-12
CN104968662B (en) 2018-03-30
ME03516B (en) 2020-04-20
IL259824A (en) 2018-07-31
KR102199258B1 (en) 2021-01-06
BR112015018033B1 (en) 2023-02-14
TWI606048B (en) 2017-11-21
IL239940B (en) 2018-07-31
MX364483B (en) 2019-04-26
EP2952513A4 (en) 2015-12-09
PH12018500261B1 (en) 2018-09-10
RS59371B1 (en) 2019-11-29
PL2952513T3 (en) 2020-01-31
DK2952513T3 (en) 2019-09-02
SI2952513T1 (en) 2019-08-30
US20150376174A1 (en) 2015-12-31
NZ709407A (en) 2019-09-27

Similar Documents

Publication Publication Date Title
ZA201505397B (en) Novel pyrazole derivative
HK1215795A1 (en) Amatoxin derivatives
EP2970281A4 (en) Substituted benzene compounds
SG11201506100XA (en) Pyridazinone-amides derivatives
HK1215806A1 (en) Azole benzene derivative
RS56211B1 (en) Oxoquinazolinyl-butanamide derivatives
PL3087076T3 (en) Imidazopyrazinone derivatives
HK1214588A1 (en) Phenyl derivative
HRP20180644T1 (en) Pyrazole derivative
EP3009444A4 (en) Alpha-oxoacyl amino-caprolactam derivative